Allergan Drops Development of siRNA Rx for AMD on Poor Phase II Data | GenomeWeb

Allergan has halted development of its siRNA-based wet age-related macular degeneration treatment AGN-745 after the drug failed to meet a key efficacy endpoint in a phase II study, a company spokeswoman confirmed this week.

The trial was comparing the effect of three different monthly doses of AGN-745 with Genentech's antibody drug Lucentis, the standard of care for AMD, in treating the subfoveal choroidal neovascularization associated with the disease. Both drugs are administered via intravitreal injection.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.